Corbus Pharmaceuticals Holdings, Inc.— Sankey Diagram
Quarterly mode · period ending 2024-09-30 · SEC EDGAR
ComparingFY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)
Revenue
$2M
Gross Profit
$2M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2024 (Q1+Q2+Q3+Q4) | FY2023 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $2M | $0 |
| COGS | $0 | $0 |
| Gross Profit | $2M | $0 |
| R&D | $23M | $30M |
| SG&A | $0 | $0 |
| D&A | $454K | $766K |
| Other OpEx | $0 | $330K |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · CRBP · Comparing FY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)